Medi Assist Q2 results landed late on Sunday, and the company chose to lead with half-year numbers rather than the quarter alone. For H1 FY27, operating revenue rose 13.0% year-on-year to ₹478.0 crore and operating EBITDA grew 19.0% to ₹97.2 crore, according to the press release Medi Assist filed on NSE. The board also approved a share buyback of up to about ₹49.3 crore.
Medi Assist calls itself India’s largest group health administrator. In plain terms, it is a third-party administrator (TPA) that sits between health insurers, policyholders and hospitals, processing claims and running the paperwork that most of us only notice when a cashless claim gets stuck.
Medi Assist Q2 results: margins did the heavy lifting
EBITDA grew faster than revenue, and that is the core of this update. The H1 EBITDA margin was 20.3%, up 103 basis points from a year ago. The September quarter was better still: the Q2 FY27 margin was 20.4%, up 331 basis points. The company puts this down to integration costs from its Paramount acquisition falling away now that the business is fully absorbed.
Further down the P&L, the growth looks sharper. Profit before tax rose 47.0% year-on-year for the half and profit after tax rose 59.5%, as per the release. It did not give the rupee amounts for PBT or PAT in the press release, so we are sticking to the growth rates it reported. Group revenue, a wider measure than operating revenue, grew 13.7% in H1.
Market share and the technology push
Total premiums under management across its platform and TPA businesses reached ₹24,752 crore. In group health, which is Medi Assist’s home turf, premiums under management grew 21.8% to ₹13,939 crore in H1. The company says that was 650 basis points faster than the industry, and its group health market share rose 182 basis points to 34.1%, with client retention of 90.5%.
The smaller but faster-moving line is technology. SaaS and licensing revenue grew 83.8% to ₹18.1 crore in H1, and 112.6% in Q2 alone. Three of the seven insurers that have contracted for its platform are fully live; the other four are scheduled to go live in H2 FY27. Platform premiums for the half were ₹9,648 crore. The company also says its fraud-detection tool, MAven Guard, stopped ₹304 crore of fraud, waste and abuse.
The international arm, Mayfair We Care, is still slow. Its revenue was ₹10.7 crore in Q2 (up 7.7%) and ₹20.7 crore in H1 (up just 1.1%). Management is counting on new platform go-lives in Thailand, Laos and Cambodia, plus travel insurance tie-ups it says cover about half of Indian travel premiums, to lift it in the second half.
The buyback, and what to watch
Medi Assist is debt-free, with ₹268.3 crore in cash and cash equivalents. The buyback of up to about ₹49.3 crore will be funded from internal operating cash flows, and the company says it uses less than a fifth of its accumulated cash reserves. The stated aim is to improve return on equity while keeping enough cash for product development and overseas growth. The release does not yet give the buyback price, size in shares or route, so those details should follow in a separate filing. Our explainer on tender offer versus open market buybacks covers what each route usually means for shareholders.
From here, we’d keep an eye on two things. First, whether the four remaining insurers actually go live on the technology stack in H2, since that is what turns the SaaS line from a small number into a meaningful one. Second, whether the Q2 margin of 20.4% holds once the easy comparison from integration costs is gone. If you want a framework for reading results like these, our guide on how to analyse quarterly results walks through it.
Disclaimer: This article is for information and education only and is not investment advice. Please do your own research or consult a SEBI-registered adviser before making any investment decision.





Leave a Reply
Join the conversation
Commenting is open to registered readers. Sign up with just your email — no password needed, and it takes under a minute.
Sign up to comment Log in